Mitochondrial Biomarkers in the Omics Era: A Clinical-Pathophysiological Perspective.
Jacopo GervasoniAniello PrimianoMichela CicchinelliLavinia SantucciSerenella ServideiAndrea UrbaniGuido PrimianoFederica IavaronePublished in: International journal of molecular sciences (2024)
Mitochondrial diseases (MDs) affect 4300 individuals, with different ages of presentation and manifestation in any organ. How defects in mitochondria can cause such a diverse range of human diseases remains poorly understood. In recent years, several published research articles regarding the metabolic and protein profiles of these neurogenetic disorders have helped shed light on the pathogenetic mechanisms. By investigating different pathways in MDs, often with the aim of identifying disease biomarkers, it is possible to identify molecular processes underlying the disease. In this perspective, omics technologies such as proteomics and metabolomics considered in this review, can support unresolved mitochondrial questions, helping to improve outcomes for patients.
Keyphrases
- oxidative stress
- mass spectrometry
- end stage renal disease
- endothelial cells
- ejection fraction
- single cell
- newly diagnosed
- chronic kidney disease
- type diabetes
- cell death
- randomized controlled trial
- systematic review
- single molecule
- protein protein
- weight loss
- binding protein
- metabolic syndrome
- induced pluripotent stem cells
- amino acid
- case report